NAV

Pancrelipase lipase

Identification

总结

Pancrelipase lipaseis a lipase used to treat pancreatic exocrine insufficiency.

Brand Names
Cotazym, Creon, Pancrease MT, Pancreaze, Pertzye, Viokace, Zenpep
Generic Name
Pancrelipase lipase
DrugBank Accession Number
DB13147
Background

Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.3The pancrelipase lipase is an enzyme secreted by the pancreas that is responsible for the hydrolysis of dietary fat molecules in the human digestive system.1The pancrelipase mixture, including pancrelipase lipase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.4

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Other protein based therapies
Protein Structure
Protein Chemical Formula
Not Available
Protein Average Weight
48000.0 Da
Sequences
>sp|P00591|LIPP_PIG Pancreatic triacylglycerol lipase OS=Sus scrofa OX=9823 GN=PNLIP PE=1 SV=2 SEVCFPRLGCFSDDAPWAGIVQRPLKILPWSPKDVDTRFLLYTNQNQNNYQELVADPSTI TNSNFRMDRKTRFIIHGFIDKGEEDWLSNICKNLFKVESVNCICVDWKGGSRTGYTQASQ NIRIVGAEVAYFVEVLKSSLGYSPSNVHVIGHSLGSHAAGEAGRRTNGTIERITGLDPAE PCFQGTPELVRLDPSDAKFVDVIHTDAAPIIPNLGFGMSQTVGHLDFFPNGGKQMPGCQK NILSQIVDIDGIWEGTRDFVACNHLRSYKYYADSILNPDGFAGFPCDSYNVFTANKCFPC PSEGCPQMGHYADRFPGKTNGVSQVFYLNTGDASNFARWRYKVSVTLSGKKVTGHILVSL FGNEGNSRQYEIYKGTLQPDNTHSDEFDSDVEVGDLQKVKFIWYNNNVINPTLPRVGASK ITVERNDGKVYDFCSQETVREEVLLTLNPC
>sp|P02703|COL_PIG Colipase OS=Sus scrofa OX=9823 GN=CLPS PE=1 SV=3 MEKVLALLLVTLTVAYAVPDPRGIIINLDEGELCLNSAQCKSNCCQHDTILSLSRCALKA RENSECSAFTLYGVYYKCPCERGLTCEGDKSLVGSITNTNFGICHDVGRSSD
Download FASTA Format
Synonyms
  • Lipase, pancreatic
  • Pancreatic lipase

Pharmacology

Indication

Please refer toPancrelipase.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Please refer toPancrelipase.

Mechanism of action

Pancrelipase lipase catalyzes the hydrolysis of triglycerides to monoglycerides, glycerol, and fatty acids. This activity is performed by the hydrolyzation of the esters of fatty acids. The hydrolysis is started by the action of colipase which helps to anchor lipase to the lipid-water membrane of the micelle producing a surface change on lipase. The hydrophobic active site is exposed for the binding of triglycerides and further interaction with the catalytic triad. In this triad, the function of the three amino acids allows the formation of a deprotonated serine which becomes a nucleophile and act on the ester carbonyl of the fatty acids for the later formation of monoglyceride and fatty acid monomers.2

Target Actions Organism
ADietary fat
cleavage
 Humans
Absorption

Please refer toPancrelipase.

Volume of distribution

Please refer toPancrelipase.

Protein binding

Please refer toPancrelipase.

Metabolism

Please refer toPancrelipase.

Route of elimination

Please refer toPancrelipase.

Half-life

Please refer toPancrelipase.

Clearance

Please refer toPancrelipase.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Please refer toPancrelipase.

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

的相互作用

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
  • Take with food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Images
Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image
Formula C & E Tablet 150 unit Oral Abundance Naturally Ltd 1998-01-05 2006-06-16 Canada flag
Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
Cotazym Pancrelipase lipase(10000 units)+Pancrelipase amylase(40000 units)+Pancrelipase protease(35000 units) Capsule Oral Organon Canada Inc. 1973-12-31 Not applicable Canada flag
Cotazym Ecs 20 Pancrelipase lipase(25000 units)+Pancrelipase amylase(100000 units)+Pancrelipase protease(100000 units) Capsule, delayed release Oral Organon Canada Inc. 1989-12-31 Not applicable Canada flag
Cotazym Ecs 4 Pancrelipase lipase(4000 unit)+Pancrelipase amylase(11000 unit)+Pancrelipase protease(11000 unit) Capsule Oral Merck Ltd. 1997-08-18 2012-01-23 Canada flag
Cotazym Ecs 8 Pancrelipase lipase(10800 units)+Pancrelipase amylase(42000 units)+Pancrelipase protease(45000 units) Capsule, delayed release Oral Organon Canada Inc. 1980-12-31 Not applicable Canada flag
Creon Pancrelipase lipase(3000 [USP'U]/1)+Pancrelipase amylase(15000 [USP'U]/1)+Pancrelipase protease(9500 [USP'U]/1) Capsule, delayed release Oral AbbVie Inc. 2009-04-30 Not applicable US flag
Creon Pancrelipase lipase(12000 [USP'U]/1)+Pancrelipase amylase(60000 [USP'U]/1)+Pancrelipase protease(38000 [USP'U]/1) Capsule, delayed release pellets Oral 医生总保健公司. 2009-09-29 Not applicable US flag
Creon Pancrelipase lipase(6000 [USP'U]/1)+Pancrelipase amylase(30000 [USP'U]/1)+Pancrelipase protease(19000 [USP'U]/1) Capsule, delayed release pellets Oral AbbVie Inc. 2009-04-30 Not applicable US flag
Creon Pancrelipase lipase(24000 [USP'U]/1)+Pancrelipase amylase(120000 [USP'U]/1)+Pancrelipase protease(76000 [USP'U]/1) Capsule, delayed release pellets Oral AbbVie Inc. 2009-04-30 Not applicable US flag
Creon Pancrelipase lipase(12000 [USP'U]/1)+Pancrelipase amylase(60000 [USP'U]/1)+Pancrelipase protease(38000 [USP'U]/1) Capsule, delayed release pellets Oral Atlantic Biologicals Corps. 2010-08-13 Not applicable US flag
Creon Pancrelipase lipase(36000 [USP'U]/1)+Pancrelipase amylase(180000 [USP'U]/1)+Pancrelipase protease(114000 [USP'U]/1) Capsule, delayed release pellets Oral AbbVie Inc. 2013-03-14 Not applicable US flag
Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image
Creon 10 Minimicrospheres Pancrelipase lipase(10000 [USP'U]/1)+Pancrelipase amylase(33200 [USP'U]/1)+Pancrelipase protease(37500 [USP'U]/1) Capsule, delayed release Oral 医生总保健公司. 2006-09-12 2009-09-30 US flag
Creon 20 Minimicrospheres Pancrelipase lipase(20000 [USP'U]/1)+Pancrelipase amylase(66400 [USP'U]/1)+Pancrelipase protease(75000 [USP'U]/1) Capsule, delayed release Oral 医生总保健公司. 1995-01-17 2009-09-30 US flag
Pancrelipase Pancrelipase lipase(20000 [USP'U]/1)+Pancrelipase amylase(56000 [USP'U]/1)+Pancrelipase protease(44000 [USP'U]/1) Capsule, delayed release Oral Kaiser Foundations Hospitals 2010-02-01 2010-12-31 US flag

Categories

Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
8MYC33932O
CAS number
9001-62-1

参考文献

一般References
  1. Chapus C, Rovery M, Sarda L, Verger R: Minireview on pancreatic lipase and colipase. Biochimie. 1988 Sep;70(9):1223-34. [Article]
  2. Chapus C, Semeriva M, Bovier-Lapierre C, Desnuelle P: Mechanism of pancreatic lipase action. 1. Interfacial activation of pancreatic lipase. Biochemistry. 1976 Nov 16;15(23):4980-7. [Article]
  3. Creon monograph [Link]
  4. FDA approval [Link]
PubChem Substance
347911431
RxNav
1427018
Wikipedia
Pancreatic_lipase_family
FDA label
Download (483 KB)
MSDS
Download (62.3 KB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
4 Active Not Recruiting Treatment Cystic Fibrosis (CF)/Pancreatitis, Chronic 1
4 Completed Treatment Cystic Fibrosis (CF) 1
4 Completed Treatment Cystic Fibrosis (CF)/Exocrine Pancreatic Insufficiency 2
4 Completed Treatment Exocrine Pancreatic Insufficiency/Pancreatitis, Chronic 1
4 Completed Treatment Pancreatic Insufficiency 1
4 Completed Treatment Pancreatitis, Chronic 1
4 Terminated Treatment Exocrine Pancreatic Insufficiency 1
4 Terminated Treatment Patients With Coeliac Disease and Chronic Diarrhoea (>3 Loose/ Liquid Motions a Day for More Than 4 Weeks)/Patients With Pancreatic Exocrine Insufficiency 1
4 Withdrawn Treatment Exocrine Pancreatic Insufficiency 1
4 Withdrawn Treatment Exocrine Pancreatic Insufficiency in Subjects With Diabetes Mellitus Type 2 1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Form Route Strength
Capsule, delayed release pellets Oral
Capsule, delayed release Oral
Capsule, delayed release pellets Not applicable
Capsule, delayed release pellets
Granule, delayed release Oral
Capsule Oral
Tablet, coated Oral
Capsule, coated pellets Oral
Tablet Oral 150 unit
Capsule, extended release Oral
Capsule, coated Oral 22500 U Ph.Eu
Tablet Oral
Powder Oral
Prices
Not Available
Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region
US9198871 No 2015-12-01 2030-02-07 US flag
US8562979 No 2013-10-22 2028-02-20 US flag
US8562980 No 2013-10-22 2028-02-20 US flag
US8562981 No 2013-10-22 2028-02-20 US flag
US8221747 No 2012-07-17 2028-02-20 US flag
US8562978 No 2013-10-22 2028-02-20 US flag
US8246950 No 2012-08-21 2028-02-20 US flag
US7658918 No 2010-02-09 2028-02-20 US flag

Properties

State
Solid
Experimental Properties
Property Value Source
water solubility Slightly soluble 'MSDS'
isoelectric point 7.4 Iizuka K. et al. 1991. Ann clin Biochem.

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
1. Dietary fat
Kind
Group
Organism
Humans
Pharmacological action
Yes
Actions
Cleavage
参考文献
  1. Chapus C, Semeriva M, Bovier-Lapierre C, Desnuelle P: Mechanism of pancreatic lipase action. 1. Interfacial activation of pancreatic lipase. Biochemistry. 1976 Nov 16;15(23):4980-7. [Article]

Drug created at November 16, 2016 15:28 / Updated at April 30, 2023 03:04